[Danazol in the therapy of dysfunctional uterine hemorrhage in women of fertility age]

Minerva ginecologica · 1989 · vol. 41(5) , pp. 219–23 · PMID:2771133 · W2422546731
Other OA: closed CC0
View on OpenAlex View on PubMed
⚙ AI-generated summary by qwen3.7-flash, 2026-10-05 ⓘ

Danazol at 200 mg/day effectively treated dysfunctional uterine hemorrhage in women without associated genital pathology, with sustained efficacy and manageable side effects.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The effectiveness of Danazol in a dose of 200 mg/day for 3 consecutive months has been assessed in 30 women complaining of dysfunctional uterine haemorrhages. The patients were selected by excluding any associated genital pathology (myomas, ovarian neoformations, endometrial cancer, etc.) and any clotting pathology. Danazol proved effective in all cases treated. Side-effects were inconsequential save for 2 women who had to suspend treatment following increase in transaminases in one case and defluvium capitis in the other. The treatment remained effective for at least 2 months after termination. In 26% of the women, the haemorrhagic pathology reappeared within 6 months but, apart from one case, repetition of the cycle using the same modalities as before, mastered and normalised the menstrual picture.

My notes (saved in your browser only)

MeSH descriptors

Danazol Pregnadienes Uterine Hemorrhage Adult Danazol Drug Evaluation Female Humans Menstruation Menstruation Middle Aged Pregnadienes Uterine Hemorrhage

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:18:43.609252+00:00
License: CC0 · commercial use OK